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Introduction
The non-Hodgkin's Lymphomas (NHL) represents a heterogeneous group of lymphoid neoplasms. Their prevalence has been increasing over the years and NHL have become fifth in cancer incidence and mortality (1, 2) . Diffuse Large B-Cell lymphoma (DLBCL) is the most common NHL, followed by Follicular Lymphoma (FL) (2-4). Since the 1970s, the best treatment option for patients with B-cell NHL consisted of various combinations of chemotherapy with or without radiotherapy (5-7). During the last decade, inclusion of the monoclonal CD20 antibody rituximab (Mabthera, Rituxan, IDEC-C2B8) in the chemotherapy regimens has significantly improved patient outcome with or without pre-treatment (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and is now accepted as a standard therapy for CD20-positive lymphomas. Furthermore, if patients with low-grade lymphoma respond to a single-agent rituximab treatment, scheduled maintenance therapy with rituximab substantially prolongs the progression free survival and overall survival (2, 18). In addition, if patients achieve complete or partial remission after the combination of chemotherapy and rituximab, maintenance with rituximab also increased the overall and progression free survival (2, [17] [18] [19] Next to its application in hematological cancers, depletion of B cells by rituximab has also shown promise for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) (20, 21) .
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Despite the success of rituximab, resistance to treatment by this therapeutic antibody develops in patients who therefore do not respond or relapse. The mechanisms of rituximab resistance may be host and/or tumor-related, but are still poorly understood (22) (23) (24) (25) . Therefore, the need to study rituximab-resistance as well as the development of more potent CD20-directed immunotherapy is imperative.
Rituximab is a chimeric human-mouse CD20 monoclonal antibody (mAb) which activates different effector mechanisms among which complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) are considered the most important (25) (26) (27) (28) (29) . In addition, growth arrest and the induction of apoptosis have been observed, especially after hyper-crosslinking of CD20 (25, 26, 30) . In previous experiments, we demonstrated that the CDC activity of rituximab significantly correlates with the number of CD20 molecules on the cell surface, and that CDC and ADCC show an additive effect. Importantly, we also showed that low CD20 (CD20 low ) expressing cells could not be killed by rituximab (29, 31, 32) . This may explain the poor response to rituximab of B-cell malignancies expressing low CD20 levels such as B-cell chronic lymphocytic leukemia B-CLL. The number of CD20 molecules on B-CLL was reported to be in the order 22,000 molecules per cell (33) , which is 300 to 600-fold lower than observed in lymphoma (29, (33) (34) (35) .
Recently, a panel of fully human antibodies including ofatumumab (HuMax-CD20),
HuMab-2C6 and HuMab-7D8, were generated in human Ig transgenic mice. This group of human antibodies represents a panel of CD20 mAbs that bind to a unique membraneproximal CD20 epitope, including the small and large extracellular loop. It has been
proposed that the recognition of this epitope leads to exceptionally potent complementmediated tumor cell lysis (32) . HuMab-7D8 and ofatumumab in addition have a much slower off-rate than rituximab (31) . Ofatumumab is currently in clinical development for B-CLL, NHL and RA (36, 37) .
Here, we investigated whether a human antibody directed against the distinct membraneproximal epitope on CD20 (HuMab-7D8) could overcome the rituximab CD20-expression level-related resistance by comparing the activity of rituximab and HuMab-7D8 in vitro and in vivo using CD20-transduced T-cells. In a xenograft mouse model we demonstrated that, although the differential effect of rituximab and HuMab-7D8 were not reflected in differences in the incresase of survival time, it was evident however, that rituximab poorly killed CD20 low -expressing cells, while HuMab-7D8 eradicated all CD20-expressing cells from the peripheral compartment as well as from the bone marrow. In vitro results demonstrate that HuMab-7D8 showed a higher capacity to kill low CD20-expressing cells than rituximab. We further show that cells that resist killing through rituximab exposure are still sensitive to HuMab-7D8.
Design and Methods

Generation of CD20-pos CEM cells and CD20-pos + lucR-IRES-eGFPpos CEM cells.
CEM T-cells were transduced with the CD20-encoding retroviral vector as previously described (29) . Briefly, the Moloney Murine-Leukemia virus based vector (pMX), containing the click beetle luciferase (LucR) and internal ribosomal entry site-enhanced
Green Fluorescent Protein (IRES-eGFP) genes, was constructed by digesting the pCBRControl vector (Promega Corporation, Madison Wi, USA) with Bgl II and X b a I endonuclease restriction enzymes, releasing the click beetle luciferase fragment.
Subsequently, the pMX-IRES-eGFP vector was digested with BamH I and Not I to create the insertion space for the LucR fragment. Next, the Xba I site of the LucR fragment and the Not I site of the viral backbone were blunted and subsequently the LucR fragment was ligated into the retroviral backbone.
Transduction of CEM-CD20 cells with the pMX-LucR-IRES-eGFP retroviral vector and generation of viral supernatant was performed as previously described (29) . Transduced CEM-CD20-LucR-IRES-eGFP cells were purified with a fluorescence-activated cell sorter (FACS) (FACSAria, Becton Dickinson, Mountain View, CA, USA) based on eGFP expression. In vitro luciferase expression was determined with a luminometer (EG&G Berthold, Lumat LB 5507) by lysing 0.1 x 10 6 cells with 100 mL lysing solution and adding 100 mL of luciferase substrate according to the manufacturer's protocol (Promega Corporation.)
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Cell culture
The CEM T-cells were cultured in culture medium consisting of RPMI (Gibco-BRL, Paisly, Scotland) supplemented with 10% fetal calf serum (FCS, Integro, Zaandam, the Netherlands), penicillin (100 U/ml), streptomycin (100 mg/ml) (Gibco-BRL), and 5 x 10 -5 M 2-mercaptoethanol (Merck, Darmstadt, Germany). All cells were cultured at 37°C in a humidified 5% CO 2 atmosphere.
Flowcytometric analysis
Expression of CD20 and eGFP was determined by flow cytometry (FACS Calibur, Becton Dickinson, Mountain View, CA, USA). Antibodies used for staining were CD20-phycoerythrin (PE) mAb/ allophycocyanin (APC), CD7-fluorescein isothiocyanate represent the absolute number of CD20 molecules per cell.
Anti-CD20 mediated cytotoxicity assays
All CD20 mAb mediated cytotoxicity assays were performed as previously described (29, 37) . Based on optimization assays, we used 10 mg/ml of anti-CD20 mAb, 20% normal human serum as source of complement, and incubated for 30 minutes at 37°C.
To study complement-dependent-cytotoxicity (CDC) mediated antibody resistance, 
Measurement of raft-associated antigen by Triton X-100 insolubility
To study the presence of CD20 in cholesterol-rich microdomains before and after antibody ligation, a rapid flow cytometry method based on Triton X-100 insolubility was performed at low temperature, as described previously (31) . Briefly, cells were washed in phosphate buffered saline (PBS) and resuspended at 2.5 x 10 6 cells/ml. Cells were incubated with 10 mg/ml of CD20 antibody (rituximab or HuMab-7D8) for 15 minutes at 37°C. Next, the samples were washed in cold PBS and then divided in half. One half was kept on ice and was used to determine the surface CD20 expression (set at 100%). The other half was treated with 0.5% Triton X-100 (Riedel-de Haen, Seelze, Germany) for 15 minutes on ice to determine the proportion of CD20 remaining in the Triton X-100-insoluble fraction. Both the treated and non-treated control cell fraction were centrifuged and stained with anti-human IgG-FITC. As a control, CD7-FITC mAb was used as described previously (29) . The mean fluorescence intensity (MFI) was determined by flow cytometry. or different doses of anti-CD20 antibody were administrated intraperitoneally (i.p). After one week, human or chimeric immunoglobuline subtype G1 (IgG1) levels were determined in serum samples of the mice. Mice lacking human or chimeric IgG1 in the serum were excluded from the analyses.
Mice, conditioning regimen and transplantation
RAG2
Bioluminescent Imaging (BLI)
Mice were monitored for luciferase expression twice a week using a cooled chargecoupled device (CCCD) camera (Roper Scientific, Princeton instrument, Trenton, NJ, USA). Mice were anaesthetized by intramuscular injection of Ketamine/Xylazin/Atropine (ratio 8:7:1, 35 _l). Subsequently, 100 _l of D-luciferin (7.5 mM) (Synchem, Kessel, Germany) was injected intraperitonealy (ip) and the ventral side of the mice was imaged for 10 minutes inside a light-tight chamber. Light emission was quantified by using
MetaVue and MetaMorph software (Universal Imaging Corporation, Downingtown, PA, USA). Blood was collected once a week to determine the serum levels of human IgG1.
Diseased and paralyzed mice were sacrificed and bone marrow (BM) was collected. Cells were harvested from the BM and the CD20-expression level was detected by flow cytometry after culture for at least 14 days.
Determination of human or chimeric IgG1 concentration
Human or chimeric IgG1 concentrations in mouse serum were determined using a 
Statistical analysis
Where indicated, the mean values and standard deviation (SD) were calculated.
Differences between rituximab and HuMab-7D8 were determined by non-linear regression curve fitting, by use of GraphPad Prism version 5.01 (GraphPad Software, Inc., San Diego, CA, USA). A p-value of < 0.05 was considered significant.
Results
Rituximab and HuMab-7D8 binding to CEM-CD20 cells and induction of CDC
Recently, fully human CD20 mAbs (ofatumumab, HuMab-7D8 and HuMab-2C6) were generated in human Ig-transgenic mice. These mAbs bind to a unique membraneproximal CD20 epitope encompassing the small and large loop of CD20 and induce ADCC and exceptionally potent CDC (31, 32) . In this study, we compared the in vitro and in vivo efficacy of rituximab and HuMab-7D8. We first tested the binding of both antibodies to the transduced CEM-CD20 cells at saturating concentrations. Figure 1A shows that both antibodies bound with similar high specificity. Next, CDC experiments were performed with CEM-CD20 cells in which the cells were incubated with antibody in the presence of normal human serum as a source of complement. For comparison, CDC was performed with both antibodies at a saturating concentration of 10 µg/ml, which was required to achieve maximal lysis with rituximab. It should be noted that maximal lysis with HuMab-7D8 was already observed at a concentration of 500 ng/ml (data not shown).
Both antibodies induced CDC very rapidly, with maximal levels occurring within 5 minutes at 37°C in the presence of 20% normal human serum (data not shown).
The influence of the CD20-expression level on CDC was assessed by employing a panel of stably transduced CEM-CD20 clones for which we determined the absolute number of CD20 molecules expressed per cell. The CD20 antibodies-bound-per cell (CD20-ABC) ranged from 7,000 to 135,000 and is comparable to CLL samples and low expressing lymphoma samples (29, (33) (34) (35) . The only variable parameter between these clones is the CD20-expression level and interpretation of results is therefore not complicated by differences in expression levels of complement regulatory proteins (CD46, CD55, CD59) (29) . The clones were subjected to rituximab-and HuMab-7D8-induced CDC, which demonstrated that rituximab required an approximately 5-6 times greater CD20
expression to induce maximum cell lysis ( Figure 1B) . By use of non-linear curve fitting a comparison was made between both treatments, evaluating differences in B max and K D using F-test. This test demonstrated that the increased CDC activity of HuMab-7D8 at low CD20-expression levels compared to rituximab was highly significant (F-test, p < 0.0001).
In addition, both antibodies were not able to induce apoptosis, as defined by propidium iodide staining in CD20 transduced CEM T-cells (data not shown).
Of note, HuMab-7D8 and rituximab were both effective in ADCC assays (data not shown). The combination of CDC and ADCC resulted in an additive killing effect for both antibodies as previously shown (data not shown) (29, 31) .
Resistance to rituximab-mediated killing of CD20 low cells cannot be explained by ineffective CD20 translocation into lipid rafts.
Both rituximab and HuMab-7D8 are able to translocate the CD20 antigen into cholesterol rich microdomains or so-called lipid rafts (31) . Efficient lipid raft formation is required for induction of CDC (38) . We addressed the question whether the higher capacity to mediate CDC of CD20 low cells was related to a superior ability of HuMab-7D8 to induce lipid raft formation compared to rituximab. To this end, we determined the induction of lipid raft formation by both antibodies using clones with different CD20-expression levels (clones A-F). Figure 1C shows that both antibodies are capable of efficiently 14 translocating CD20 molecules into lipid microdomains, independent of the CD20-expression level. At the same time, HuMab-7D8 is more effective than rituximab in mediating CDC of CEM-CD20 clones with a low surface density of CD20 ( Figure 1D ).
These data suggest that factors other than efficient translocation of CD20 molecules into lipid rich microdomains are responsible for the poor lysis of CD20 low cells by rituximab.
In vivo eradication of CD20 low cells by HuMab-7D8 but not rituximab.
To study the in vivo efficacy of both antibodies, we developed a mouse model in which For in vivo imaging, CEM cells were transduced with a CD20-expression vector (CD20-WPRE-INS) and a retroviral vector expressing luciferase and eGFP (LucR-IRES-eGFP) (38) (Figure 2A) . The CD20-WPRE-INS retroviral vector was selected because of its highly stable CD20 expression in vitro (38) . To mimic the in vivo situation in patients, we
chose not to use a clonal population of cells for this experiment. Instead, CD20 and eGFP double positive cells were purified by FACS sorting. We selected a cell population predominantly existing of CD20 low cells, but also containing cells with higher or even lower CD20 expression varying in a three log range for CD20 expression with a mean of 100 MFI ( Figure 2B ). The 90% of cells positive for eGFP and CD20, as indicated in Figure 2B , were shown to also express high levels of luciferase ( Figure 2C ). The in vitro sensitivity for rituximab-and HuMab-7D8-induced CDC of the selected pool was determined before injection into mice using a concentration of 10 _g/ml. Consistent with the low CD20 expression, rituximab induced poor CDC (10% cell lysis) compared to HuMab-7D8 (50% cell lysis) in this cell population ( Figure 2D ). After euthanizing the mice, cells were harvested from the bone marrow and cultured for at least two weeks in normal culture medium to eliminate mouse cells. Next, the CD20 expression of these cells, that survived in vivo antibody treatment, was analyzed. As a control, we confirmed that no remaining rituximab or HuMab-7D8 was present on the cell surface at that time (data not shown). Cells harvested from the control mice showed similar CD20-expression levels as the original cells that were injected into the mice ( Figure 4A and B). Cells harvested from mice treated with rituximab still expressed CD20, but at a lower level compared to the original cells ( Figure 4C ). Remarkably, cells from mice injected with HuMab-7D8 did not exhibit any CD20 expression ( Figure 4D ).
Together, these data suggest that CD20 low cells escaped CDC-mediated lysis by rituximab in vivo, while CD20 low -expressing cells were eliminated by HuMab-7D8.
CD20 low cells which escape rituximab can be killed by HuMab-7D8
We next addressed the question whether rituximab-resistant CEM-CD20 cells could be killed by HuMab-7D8 and vice versa. In parallel experiments, CD20 low CEM-CD20 cells were subjected to either rituximab-or HuMab-7D8-induced CDC using a mAb concentration of 10 _g/ml, respectively and the extent of cell death was determined using propidium iodine FACS staining (10% for rituximab versus 50% for HuMab-7D8, Figure   5A ). As a control experiment, no CDC was observed in the presence of human serum alone ( Figure 5A ) or with heat-inactivated serum (data not shown). The cells surviving rituximab or HuMab-7D8 treatment were kept in culture for 14 days and subjected to a 
Discussion
In this report, we compared the human CD20 antibody HuMab-7D8 with rituximab for its ability to overcome resistance to CD20 antibody therapy in relation to the CD20-expression level of cells. We demonstrated in vitro that compared to rituximab, HuMab-7D8 is significantly more efficient in killing CD20-transfected human CEM T leukemia cells.
HuMab-7D8 and rituximab both contain human IgG1 constant regions and have the same inherent C1q binding capacity when C1q is deposited on a plastic surface (31) . After binding to CD20 on cells, HuMab-7D8 however activates complement more efficiently than rituximab and induces superior cell lysis (31, 32, (44) (45) (46) . HuMab-7D8, together with
HuMab-2C6 and ofatumumab, the latter of which is in advanced clinical development and was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory CLL, belong to a group of human antibodies that bind to a CD20 epitope which is distinct from that recognized by all other CD20 mAbs (32) . These novel antibodies bind to a membrane-proximal epitope, which includes the small 7-mer loop of the CD20 molecule. The A170xP172 motif in the large 44-mer loop that harbours the binding site of rituximab and most other CD20 mAbs, is not relevant for binding by
HuMab-7D8 and ofatumumab-type antibodies (32) .
There are three (functional) characteristics of HuMab-7D8 that could potentially contribute to its superiority to rituximab in eliciting CDC-mediated cell killing (32) . First, there is superior binding of HuMab-7D8, resulting in a slower off-rate. However, as CDC occurs in minutes and the antibody off-rate occurs in hours to days, a slower off-rate is probably only marginally contributing to the differences in CDC induction in our in vitro experiments ( Figure 1B ). In addition, another human CD20 antibody, HuMab-2C6, identified in the same panel as HuMab-7D8, (IgG1-2C6) has a faster off-rate than rituximab, but retains a much better capacity to activate complement (32) . Second, the movement of CD20 molecules into lipid rafts is crucial for the activation of complement which therefore may be affected by differences in the efficiency of CD20 antibodies to induce such translocation (26, 39 ). Here we demonstrate however that raft formation occurs similarly for both HuMab-7D8 and rituximab independent of CD20 expression, and thus the reduced activity of rituximab against CD20 low cells is not due to inefficient raft formation ( Figures 1C and D) . A third characteristic is the proximity of the cognate epitope to the cell membrane. Binding of an antibody to the small loop epitope (HuMab- C4b and C3b thus may fixate more efficiently on the cell membrane (46) (47) (48) (49) . This might explain why HuMab-7D8 needs less CD20 molecules than rituximab for inducing cell death, and is capable of killing rituximab-resistant cells ( Figure 1B ).
In addition, we found that rituximab-resistant cells were sensitive to HuMab-7D8-mediated lysis in the presence of complement. Significantly, HuMab-7D8 treated cells that survived an initial treatment, remained sensitive to HuMab-7D8 but could not be lysed by rituximab ( Figure 5 ). complement is required for elimination of human CD20-expressing murine lymphoma cells in syngeneic mice (50) . In the studies by Golay and co-workers, killing of all human CD20-positive cells by rituximab leads to 100% survival of the mice. In our study, outgrowth of the tumor cells in the mice was not totally prevented although we did observe a significant increase in survival time for both groups of treated compared to untreated mice ( Figure 3C ). A major difference with the Golay studies is that we employed a polyclonal CD20 low human CEM cell population with varying CD20-expression levels ( Figure 1A ) and also containing CD20-negative cells. In contrast to the Golay studies, which employed a cell line homogenously expressing high levels of CD20
we therefore observed CD20 low and CD20 neg cells to grow (i.e. resulting in increasing luminescence signals over time). Indeed, surviving cells were found in the bone marrow, liver, spleen and lymph nodes, which upon analysis showed some interesting differences between rituximab-treated and HuMab-7D8-treated mice. Cells surviving in rituximabtreated mice still expressed CD20, albeit at a low level, while the surviving cells in
HuMab-7D8-treated mice were entirely CD20-negative. Whilst this is a most important observation, it is not reflected in significant differences in tumor load reduction (BLI data in Figure 3A and B) or in differences in survival times (survival curves in Figure 3C) between HuMab-7D8 and rituximab-treated mice. Our CDC data showed that the difference between rituximab and HuMab-7D8 only becomes apparent for cells with low CD20 expression, which, in our cell line, is only a minor fraction ( fig 1B) . The polyclonal CD20-positive cells that were injected in the mice, however, also contained a very small fraction of CD20-negative cells. Obviously, the latter cannot be eliminated either by rituximab or HuMab-7D8. Hence, the small difference between the fraction of nonexpressing plus low expressing cells surviving in the rituximab-treated mice versus the fraction of non-expressing cells only surviving after Humab-7D8 does not leave much room for improvement. We estimate this to be in the order of 2-fold and this will not result in significant differences in survival time or BLI signal (see also supplemental
Figure online). Thus, the most striking finding in this study is that HuMab-7D8 eradicates all CD20-expressing cells, from low to high, while rituximab only eradicates the higher CD20-expressing cells (Figure 4 ). Previously, it was described that CD20 can be transiently down-regulated by shaving of the antibody-CD20 complex by monocytes (51, 52) . It is unlikely that shaving is responsible for the effects observed here, as extended in vitro culture (14 days) of the surviving cells did not result in CD20 re-expression. The pool of CD20/eGFP-transduced CEM cells used in our in vivo mouse model contained a very low fraction of cells expressing no CD20 at all. In B cell leukemic patients, in contrast, a complete loss of CD20 appears extremely rare and has only been reported in a very small number of case reports. This, in combination with our observations in mice, suggests that escape of HuMab-7D8 therapy by down regulation of CD20 is quite unlikely.
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In conclusion, HuMab-7D8 is able to efficiently kill both CD20 high as well as CD20 initial rituximab-or Humab-7D8-mediated killing were cultured for an additional two weeks. Rituximab treated cells were subjected to a second exposure of CDC induction using either rituximab or HuMab-7D8. Conversely, the HuMab-7D8-treated cells from the first experiment were subjected to CDC induction using either rituximab or HuMab-7D8. Background lysis was assessed by adding normal human serum only. Mice received a polyclonal CD20 transduced cell population with a broad pattern of CD20-expression, from low to high but it also included a small proportion of CD20-negative cells (see for example fig 2B) . The blue line in the figure shows the exponential growth curve of CD20-CEM cells in non-treated control mice (compare BLI curve figure 3B ). The green line reflects the maximal estimated 98% cell kill that can be achieved with an antibody that kills all cells, having high or low level of CD20 expression (in this case HuMab-7D8). A small proportion of the cells does not express CD20 (in this example assumed to be 2%, see also fig 1 B ) and thus cannot be eliminated.
The red lines illustrate:
(1) assuming that a large proportion of the cells has a low level of CD20 expression (in the graph 20% is taken as an example) this would have resulted in a large difference in surviving fraction between HuMab-7D8 versus rituximab treatment because rituximab less effectively kills the cells with low CD20 expression . Although the negative cells also survive, this nevertheless would have resulted in significant differences in BLI values ("BLI1) and survival curves ("t1).
(2) assuming that only a small fraction of cells are CD20 low ,one would find that HuMab-7D8 still kills all cells except the CD20-negative cells. Rituximab obviously could not kill the negative cells but CD20 low -expressing cells would also survive. This difference is however small, and estimated to be in the order of 2-fold. The differences in the BLIderived growth curves ("BLI1) and in the survival time ("t2) are therefore small and within the variation of the assay. The latter is what we observed in this study.
